QCG
BSX icon

Quadrant Capital Group’s Boston Scientific BSX Stock Holding History

Quadrant Capital Group’s Portfolio BSX Stock Details BSX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.63M Sell
25,974
-6,622
-20% -$530K 0.05% 352
2025
Q4 		$3.11M Buy
32,596
+296
+0.9% +$29K 0.09% 161
2025
Q3 		$3.15M Sell
32,300
-1,158
-3% -$120K 0.1% 149
2025
Q2 		$3.59M Buy
33,458
+8,509
+34% +$861K 0.13% 129
2025
Q1 		$2.52M Buy
24,949
+9,991
+67% +$1.01M 0.09% 138
2024
Q4 		$1.34M Sell
14,958
-173
-1% -$15.2K 0.09% 150
2024
Q3 		$1.27M Buy
15,131
+188
+1% +$14.8K 0.09% 159
2024
Q2 		$1.15M Buy
14,943
+1,536
+11% +$112K 0.09% 171
2024
Q1 		$918K Buy
13,407
+49
+0.4% +$3.15K 0.07% 200
2023
Q4 		$772K Buy
13,358
+221
+2% +$11.8K 0.07% 212
2023
Q3 		$694K Buy
13,137
+1,235
+10% +$64.8K 0.07% 204
2023
Q2 		$644K Sell
11,902
-29
-0.2% -$1.51K 0.06% 207
2023
Q1 		$597K Buy
11,931
+858
+8% +$40.4K 0.06% 229
2022
Q4 		$512K Buy
11,073
+376
+4% +$16.3K 0.06% 234
2022
Q3 		$414K Buy
10,697
+1,035
+11% +$41.5K 0.05% 241
2022
Q2 		$360K Buy
9,662
+889
+10% +$36.2K 0.05% 278
2022
Q1 		$388K Buy
8,773
+1,258
+17% +$54.5K 0.05% 282
2021
Q4 		$319K Sell
7,515
-607
-7% -$25.5K 0.04% 326
2021
Q3 		$352K Buy
8,122
+188
+2% +$8.32K 0.05% 256
2021
Q2 		$339K Buy
7,934
+718
+10% +$30.2K 0.05% 255
2021
Q1 		$279K Buy
7,216
+870
+14% +$32.9K 0.05% 268
2020
Q4 		$228K Sell
6,346
-1,254
-17% -$45.2K 0.04% 275
2020
Q3 		$290K Sell
7,600
-1,275
-14% -$49.1K 0.06% 197
2020
Q2 		$312K Sell
8,875
-880
-9% -$31.7K 0.07% 191
2020
Q1 		$319K Sell
9,755
-3,022
-24% -$118K 0.05% 281
2019
Q4 		$554K Buy
12,777
+1,556
+14% +$65.1K 0.07% 265
2019
Q3 		$444K Buy
11,221
+3,706
+49% +$157K 0.07% 290
2019
Q2 		$311K Sell
7,515
-1,493
-17% -$57.4K 0.05% 384
2019
Q1 		$334K Buy
9,008
+2,476
+38% +$94.6K 0.06% 322
2018
Q4 		$215K Buy
6,532
+302
+5% +$11K 0.06% 324
2018
Q3 		$232K Hold
6,230
– – 0.07% 204
2018
Q2 		$193K Buy
6,230
+111
+2% +$3.35K 0.07% 239
2018
Q1 		$158K Buy
6,119
+1,035
+20% +$28.1K 0.06% 295
2017
Q4 		$114K Hold
5,084
– – 0.05% 354
2017
Q3 		$138K Hold
5,084
– – 0.06% 298
2017
Q2 		$106K Sell
5,084
-117
-2% -$3.1K 0.05% 329
2017
Q1 		$122K Buy
5,201
+487
+10% +$11.8K 0.05% 295
2016
Q4 		$97K Sell
4,714
-46
-1% -$1K 0.05% 271
2016
Q3 		$107K Sell
4,760
-84
-2% -$2K 0.07% 229
2016
Q2 		$105K Buy
4,844
+83
+2% +$1.8K 0.07% 221
2016
Q1 		$85K Sell
4,761
-41
-0.9% -$720 0.06% 250
2015
Q4 		$81K Buy
4,802
+473
+11% +$8.48K 0.06% 271
2015
Q3 		$68K Buy
4,329
+7
+0.2% +$120 0.05% 322
2015
Q2 		$74K Buy
+4,322
New +$77.2K 0.05% 328

Other funds holding BSX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Quadrant Capital Group's BSX Position: Q1 2026 in Review

Quadrant Capital Group reduced its Boston Scientific (BSX) stake by 20% in Q1 2026, selling an estimated $530K and leaving 25,974 shares worth $1.63M. The position accounts for 0.05% of the portfolio, ranked #352.

Quadrant Capital Group first reported a position in BSX in Q2 2015 and has held it in 44 quarters since. The position peaked at $3.59M in Q2 2025. 1,664 funds tracked by Wall St. Rank hold BSX as of Q1 2026.

  • Quadrant Capital Group held 25,974 shares of Boston Scientific worth $1.63M as of Q1 2026.
  • Quadrant Capital Group sold 6,622 Boston Scientific shares in Q1 2026, an estimated $530K.
  • Boston Scientific made up 0.05% of Quadrant Capital Group's portfolio in Q1 2026, its #352 holding.
  • Quadrant Capital Group first reported a position in Boston Scientific in Q2 2015 and has held it in 44 quarters since.
  • Quadrant Capital Group's Boston Scientific position peaked at $3.59M in Q2 2025.
  • 1,664 funds tracked by Wall St. Rank held Boston Scientific as of Q1 2026.

Based on Quadrant Capital Group's 13F filing for Q1 2026, filed 11 May 2026.